Taiwan Liposome Company, Ltd. - ADRs (TLC): Price and Financial Metrics


Taiwan Liposome Company, Ltd. - ADRs (TLC): $7.00

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TLC Stock Price Chart Interactive Chart >

Price chart for TLC

TLC Price/Volume Stats

Current price $7.00 52-week high $7.70
Prev. close $7.00 52-week low $4.07
Day low $7.00 Volume 12,400
Day high $7.09 Avg. volume 133,095
50-day MA $7.06 Dividend yield N/A
200-day MA $5.88 Market Cap 294.54M

Taiwan Liposome Company, Ltd. - ADRs (TLC) Company Bio


Taiwan Liposome Company, Ltd. is a Taiwan-based company principally engaged in the research and development and commercialization of lipid drug delivery systems. The Company is engaged in the development of special generic drugs, new formulas and new drugs using patents. The Company's therapeutic areas include pain management, eye diseases and cancer. Its anticancer medicine product named Lipo-Dox has been distributed in domestic and Asian markets.


TLC Latest News Stream


Event/Time News Detail
Loading, please wait...

TLC Latest Social Stream


Loading social stream, please wait...

View Full TLC Social Stream

Latest TLC News From Around the Web

Below are the latest news stories about Taiwan Liposome Company Ltd that investors may wish to consider to help them evaluate TLC as an investment opportunity.

TLC Announces Voluntary Delisting and Deregistration of American Depositary Shares

This communication does not constitute an offer of any securities for sale or subscription or a solicitation of an offer to purchase or subscribe to any securities in any jurisdiction. The securities to be issued pursuant to the stock swap transaction will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or under any relevant securities laws of any state or other jurisdiction of the United States. Such securities will be issued in reliance upon the exem

Yahoo | September 8, 2021

TLC Reports Second Quarter 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 12, 2021 (GLOBE NEWSWIRE) -- TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the second quarter ended June 30, 2021 and provided a business update. “The second quarter of 2021 was marked mainly by the timely approval of our liposomal amphotericin B product in India and the immediate partnerships for their commercialization and sal

Yahoo | August 12, 2021

Ropivacaine Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:AstraZeneca, PainReform Ltd, Taiwan Liposome Company, Aspen Pharmacare, Encore Therapeutics, Celgene

This report studies the Ropivacaine Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Ropivacaine market segmented by company, region, type and applications []

Jumbo News | July 25, 2021

Global Thymic Carcinoma Treatment Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Merck & Co., Inc., Sumitomo Dainippon Pharma Co., Ltd., Novartis AG, Onxeo SA, Tiziana Life Sciences Plc, Taiwan Liposome Company, Ltd.

The report on Global Thymic Carcinoma Treatment Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic []

Jumbo News | July 23, 2021

Short Squeeze Stocks: XELA, NEGG and 3 Other Stocks Experts Think Are Ready to Pop

Looking for the next AMC, retail investors are on the hunt for the next squeeze.

Brenden Rearick on InvestorPlace | July 12, 2021

Read More 'TLC' Stories Here

TLC Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 0.43%
3-year 27.74%
5-year N/A
YTD N/A
2021 0.00%
2020 -17.66%
2019 -2.18%
2018 N/A
2017 N/A

Continue Researching TLC

Want to see what other sources are saying about Taiwan Liposome Company Ltd's financials and stock price? Try the links below:

Taiwan Liposome Company Ltd (TLC) Stock Price | Nasdaq
Taiwan Liposome Company Ltd (TLC) Stock Quote, History and News - Yahoo Finance
Taiwan Liposome Company Ltd (TLC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4492 seconds.